Acoramidis

H.C. Wainwright raises BridgeBio Pharma's price target to $49.00 from $43.00, maintaining a Buy rating, following FDA approval of Attruby for ATTR-CM. Attruby, priced at $18,759.12 for a 28-day supply, is expected to generate sales early next year. BridgeBio's market cap is $4.43 billion, with negative operating income of -$516.2 million, highlighting the significance of Attruby's commercialization.

The FDA approved acoramidis (Attruby), an oral transthyretin stabilizer for adults with ATTR-CM, reducing cardiovascular death and hospitalization. This first-of-its-kind therapy, designed to mimic a natural TTR gene mutation, was supported by the ATTRibute-CM trial, showing improved outcomes in ATTR-CM patients.

Attruby, the first FDA-approved near-complete TTR stabilizer, significantly reduces cardiovascular death and hospitalizations in ATTR-CM patients, with rapid benefits seen in as few as 3 months. BridgeBio will provide Attruby free for life to U.S. clinical trial participants and offers extensive access programs. The company is set to receive $500 million under a royalty funding agreement and plans global expansion, with European approval expected in 2025.

BridgeBio Pharma's Attruby™, FDA-approved for ATTR-CM, significantly reduces cardiovascular death and hospitalizations, showing benefits as early as 3 months. It stabilizes TTR, preserving its transport function, and offers hope for amyloidosis patients. BridgeBio provides Attruby free for life to U.S. trial participants.

BridgeBio Pharma's Attruby (acoramidis) approved by FDA for ATTR-CM, reducing cardiovascular death and hospitalization. Positive ATTRibute-CM Phase 3 results led to $500 million payment. European MAA submitted, with Bayer granted exclusive rights for commercialization.

FDA approves BridgeBio Pharma's Attruby (acoramidis) for transthyretin amyloidosis cardiomyopathy, priced at $244,000 annually. The drug stabilizes misfolded TTR protein, showing survival and hospitalization benefits. Market competition heats up with Pfizer's tafamidis and potential rivals. BridgeBio aims for 30% market share, planning head-to-head trials.

FDA approves Attruby™ (acoramidis) for ATTR-CM, a rare heart disease, offering a new treatment option. Attruby stabilizes TTR protein, reducing amyloid formation and disease progression. BridgeBio provides free access for trial participants and support via ForgingBridges™ program.

Attruby, the first FDA-approved near-complete TTR stabilizer, reduces cardiovascular death and hospitalizations in ATTR-CM patients, with rapid benefits seen in as few as 3 months. BridgeBio will provide Attruby free for life to U.S. clinical trial participants and offers extensive access programs.